384 related articles for article (PubMed ID: 33767701)
1. Immunogenicity Risk Profile of Nanobodies.
Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
Front Immunol; 2021; 12():632687. PubMed ID: 33767701
[TBL] [Abstract][Full Text] [Related]
2. Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells.
Rossotti M; Tabares S; Alfaya L; Leizagoyen C; Moron G; González-Sapienza G
Biochim Biophys Acta; 2015 Jul; 1850(7):1397-404. PubMed ID: 25819371
[TBL] [Abstract][Full Text] [Related]
3. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
4. Engineered cross-reacting nanobodies simplify comparative oncology between humans and dogs.
Mazzega E; de Marco A
Vet Comp Oncol; 2018 Mar; 16(1):E202-E206. PubMed ID: 29047203
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies and Cancer: Current Status and New Perspectives.
Allegra A; Innao V; Gerace D; Vaddinelli D; Allegra AG; Musolino C
Cancer Invest; 2018 Apr; 36(4):221-237. PubMed ID: 29658806
[TBL] [Abstract][Full Text] [Related]
6. A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV.
Zhao G; He L; Sun S; Qiu H; Tai W; Chen J; Li J; Chen Y; Guo Y; Wang Y; Shang J; Ji K; Fan R; Du E; Jiang S; Li F; Du L; Zhou Y
J Virol; 2018 Sep; 92(18):. PubMed ID: 29950421
[TBL] [Abstract][Full Text] [Related]
7. Phase I Study of 68Ga-HER2-Nanobody for PET/CT Assessment of HER2 Expression in Breast Carcinoma.
Keyaerts M; Xavier C; Heemskerk J; Devoogdt N; Everaert H; Ackaert C; Vanhoeij M; Duhoux FP; Gevaert T; Simon P; Schallier D; Fontaine C; Vaneycken I; Vanhove C; De Greve J; Lamote J; Caveliers V; Lahoutte T
J Nucl Med; 2016 Jan; 57(1):27-33. PubMed ID: 26449837
[TBL] [Abstract][Full Text] [Related]
8. A guide to: generation and design of nanobodies.
Muyldermans S
FEBS J; 2021 Apr; 288(7):2084-2102. PubMed ID: 32780549
[TBL] [Abstract][Full Text] [Related]
9. Size-advantage of monovalent nanobodies against the macrophage mannose receptor for deep tumor penetration and tumor-associated macrophage targeting.
Erreni M; D'Autilia F; Avigni R; Bolli E; Arnouk SM; Movahedi K; Debie P; Anselmo A; Parente R; Vincke C; van Leeuwen FWB; Allavena P; Garlanda C; Mantovani A; Doni A; Hernot S; Van Ginderachter JA
Theranostics; 2023; 13(1):355-373. PubMed ID: 36593955
[No Abstract] [Full Text] [Related]
10. Enhanced Ability of Oligomeric Nanobodies Targeting MERS Coronavirus Receptor-Binding Domain.
He L; Tai W; Li J; Chen Y; Gao Y; Li J; Sun S; Zhou Y; Du L; Zhao G
Viruses; 2019 Feb; 11(2):. PubMed ID: 30791410
[TBL] [Abstract][Full Text] [Related]
11. Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology.
Lin K; Xia B; Wang X; He X; Zhou M; Lin Y; Qiao Y; Li R; Chen Q; Li Y; Feng J; Chen T; Chen C; Li X; Zhang H; Lu L; Liu B; Zhang X
J Transl Med; 2024 Apr; 22(1):349. PubMed ID: 38610029
[TBL] [Abstract][Full Text] [Related]
12. Development and evaluation of nanobody tracers for noninvasive nuclear imaging of the immune-checkpoint TIGIT.
Zeven K; De Groof TWM; Ceuppens H; Awad RM; Ertveldt T; de Mey W; Meeus F; Raes G; Breckpot K; Devoogdt N
Front Immunol; 2023; 14():1268900. PubMed ID: 37799715
[TBL] [Abstract][Full Text] [Related]
13. Targeting breast carcinoma with radioiodinated anti-HER2 Nanobody.
Pruszynski M; Koumarianou E; Vaidyanathan G; Revets H; Devoogdt N; Lahoutte T; Zalutsky MR
Nucl Med Biol; 2013 Jan; 40(1):52-9. PubMed ID: 23159171
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy.
Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P
J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364
[TBL] [Abstract][Full Text] [Related]
15. PET Imaging of Macrophage Mannose Receptor-Expressing Macrophages in Tumor Stroma Using 18F-Radiolabeled Camelid Single-Domain Antibody Fragments.
Blykers A; Schoonooghe S; Xavier C; D'hoe K; Laoui D; D'Huyvetter M; Vaneycken I; Cleeren F; Bormans G; Heemskerk J; Raes G; De Baetselier P; Lahoutte T; Devoogdt N; Van Ginderachter JA; Caveliers V
J Nucl Med; 2015 Aug; 56(8):1265-71. PubMed ID: 26069306
[TBL] [Abstract][Full Text] [Related]
16. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies.
Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S
Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966
[TBL] [Abstract][Full Text] [Related]
17. An innovative approach in the detection of Toxocara canis excretory/secretory antigens using specific nanobodies.
Morales-Yanez FJ; Sariego I; Vincke C; Hassanzadeh-Ghassabeh G; Polman K; Muyldermans S
Int J Parasitol; 2019 Jul; 49(8):635-645. PubMed ID: 31150611
[TBL] [Abstract][Full Text] [Related]
18. Nanobody-targeted photodynamic therapy induces significant tumor regression of trastuzumab-resistant HER2-positive breast cancer, after a single treatment session.
Deken MM; Kijanka MM; Beltrán Hernández I; Slooter MD; de Bruijn HS; van Diest PJ; van Bergen En Henegouwen PMP; Lowik CWGM; Robinson DJ; Vahrmeijer AL; Oliveira S
J Control Release; 2020 Jul; 323():269-281. PubMed ID: 32330574
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
20. Conformational nanobodies reveal tethered epidermal growth factor receptor involved in EGFR/ErbB2 predimers.
Nevoltris D; Lombard B; Dupuis E; Mathis G; Chames P; Baty D
ACS Nano; 2015 Feb; 9(2):1388-99. PubMed ID: 25603171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
